Etihad Cargo - HOPE Consortuim
Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

04

Dec 2020

Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies

Tevard Biosciences a privatelyheld biotechnology company pioneering tRNAbased gene therapies and Zogenix a global biopharmaceutical company developing and commercializing rare disease therapies announced that the companies have entered into a collaboration to identify and develop novel tRNAbased gen...

04

Dec 2020

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

Merck KGaA Darmstadt Germany a leading science and technology company and Artios Pharma Limited Artios a leading DNA Damage Response DDR company developing a broad pipeline of precision medicines for the treatment of cancer announced a global three year strategic research collaboration to discover a...

03

Dec 2020

Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA

Tubulis WuXi STA and WuXi Biologics announced a strategic collaboration to manufacture and advance Tubulis next generation antibodydrug conjugates ADCs towards INDenabling studies Tubulis has developed a dual platform approach to generate uniquely matched and diseasespecific ADCs that combine select...

03

Dec 2020

Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

Exelixis Inc Iconic Therapeutics Inc Iconic and Zymeworks Incannounced that Exelixis has exercised its exclusive option for Iconics lead oncology antibodydrug conjugate ADC program under the companies May agreement

press releasesRead more...

04

Dec 2020

ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

ReAlta Life Sciences Incannounced that the European Medicines Agency EMA has granted Orphan Drug Designation to RLS also known as PICdPEG for the treatment of neonatal encephalopathy This designation builds on the Orphan Drug Designation that ReAlta received from the US Food and Drug Administration...

04

Dec 2020

I2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon

IO Therapeutics an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs has received a strategic investment from Colorcon Ventures the corporate venture fund of Colorcon Inc In addition to this investment Colorcon will collaborate with...

03

Dec 2020

AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

AbbVie a researchbased global biopharmaceutical company and Frontier Medicines Corp a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases announced a global strategic collaboration to discover develop and commerci...

03

Dec 2020

Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

Catalyst Biosciences Incannounced the US Food and Drug Administration FDA has granted Fast Track Designation for Marzeptacog alfa activated or MarzAA the Companys subcutaneously SQ administered nextgeneration engineered coagulation Factor VIIa FVIIa for the treatment of episodic bleeding in subject...

EventsRead more...

01 - 04

Dec 2020

Pharma and Patient USA 2020

Reuters Events
Online

02 - 04

Dec 2020

Pharma Logistics 2020

Manch Exhibitions (Thailand) Co. Ltd
Bangkok International trade and Exhibition Centre (BITEC)

03 - 05

Dec 2020

Medical, Hospital & Pharmaceutical In Hanoi

Hanoi International Exhibition Center

04 - 05

Dec 2020

TOP ARTICLES

  • 2

    Personalised Therapy

    Drugs can be formulated in the form of tablets pellets emulsion cream and many others for patient consumption...

KNOWLEDGE BANK

  • Interviews

    University of Lincoln, UK

    Senior Lecturer, School of Pharmacy

    Ishwar Singh is a Senior Lecturer in Biological Chemistry at the School of Pharmacy University of Lincoln Prior to Lincoln he had held many prestigious fellowships such as the Alexander von Humboldt fellowship Germany and Senior Research Fellowship DANIDA Denmark and CSIR India He is an organic chemist He has developed bioconjugations for DNA RNA and polymer modifications in water He is currently...
  • Articles

    Advanced Nanobots for ‘Programmed’ Biomedical Applications

    The idea of nanobots that could perform programmed tasks at targeted sites by traveling through biological fluids is no more in science fiction now Recent development in the field of nanotechnology provides the scope of designing miniaturised tiny nanobots which are even smaller than the dimension of biological cells

EDITORIAL SECTION

  • EXPERT Talk

    PHARMA LOGISTICS TRENDS

    Pharma logistics is undergoing profound change throughout Asia as the ageing population drives a growing need for new pharma solutions together with s...